Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery System – medicines that have the potential to transform the prevention and management of serious chronic diseases.
We focus our efforts on diseases that are prevalent and poorly controlled, and that are growing at an epidemic rate. This gives us a dual focus in preventive and therapeutic medicine. Our near-term goal is to deliver a game-changing new level of glycemic control for a vast number of patients with type 2 diabetes. Making a real difference in this area where little or no progress has been made in more than a decade for the majority of patients – despite numerous new pills and injections – is our future and our passion. Our longer-term goal is to expand our Medici Drug Delivery System further into diabetes/obesity treatment and its prevention, and our critical new initiative for improved global HIV prevention through a landmark collaboration with the Bill and Melinda Gates Foundation.
To unleash life’s possibilities with disruptively innovative medicines — each proven to raise the standard of care, improves lives, and to provide attractive value creation and business results. We live by our core values striving to earn and preserve the trust, respect and admiration of all our stakeholders — including our own people by providing a differentiated and fulfilling place to work.
Our values form the core of who we are and how we differentiate ourselves. They shape our actions in business and our interactions with others. Our values place “winning for patients” at the center of everything we do. Our values are not just words on a website. What distinguishes our people is that we live our values every day — at all levels and in all aspects of our Company. Learn more
Intarcia’s lead product candidate, ITCA 650 (continuous subcutaneous delivery of exenatide), completed Phase 3 development for the treatment of type 2 diabetes. Intarcia submitted the NDA for regulatory approval of ITCA 650 in the U.S. to the FDA on November 20, 2016, and the FDA accepted the NDA filing on February 3, 2017.
Our artwork is a metaphor for how we work – unleashing our talent so we can create the keys to unlock innovation so disruptive it changes the standards by which things are done, generating tremendous benefit to patients, payers and providers.
Intarcia carefully maintains an environment based on our core values of innovation and trust. We are comprised of talented and entrepreneurial people who enjoy collaborating and achieving excellent results. Our leaders are deeply experienced and extremely approachable executives who actively support our business plan and our team. Read more